Recently, the research group of Li Jingya and the research group of Minjia Tan of the Shanghai Institute of Materia Medica , Chinese Academy of Sciences, and the Gao Xin/Xia Mingfeng team of Zhongshan Hospital of Fudan University Affiliated Hospital, revealed a new molecular mechanism of mitochondrial homeostasis in non-alcoholic fatty liver disease, which is non-alcoholic fat.
Chinese Academy of Sciences In recent years, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis have spread rapidly around the world, and there are no drugs with clear targets and significant effects on the market
Mitochondrial homeostasis plays a decisive role in cell energy metabolism and signal pathway regulation, and its homeostasis is the key pathological cause of metabolic diseases such as non-alcoholic fatty liver disease and obesity
Li Jingya’s team is committed to exploring the molecular mechanism of mitochondrial homeostasis in metabolic diseases.
In this study, the research team revealed for the first time that the death-related apoptosis-inducing protein kinase DRAK2 leads to the abnormal splicing of mitochondrial-related genes (including mtDNA polymerase POLγ2) through the RNA splicing factor SRSF6 pathway, and fully demonstrated that this mitochondrial function is related Abnormal gene splicing is a key pathological molecular mechanism for the occurrence and development of non-alcoholic fatty liver disease
This work was funded by the National Natural Science Foundation of China, the National Major Science and Technology Project, the National Key Research and Development Program, and the Shanghai Natural Science Foundation of China
Related paper information: https://doi.
https://doi.
org/10.
1016/j.
cmet.
2021.
09.
008
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![2,6-Dibromo-4,4-bis(2-ethylhexyl)-4H-silolo[3,2-b:4,5-b']dithiophene](https://file.echemi.com/fileManage/upload/canonicalSmiles/20220811/27c7aefc886740ceb896628aa7d359ad.png)
![2-((2-(5-(4-(Diphenylamino)phenyl)thieno[3,2-b]thiophen-2-yl)thiazol-5-yl)methylene)malononitrile](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
